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Objective: Apolipoprotein A1 (ApoA1) is remarkably decreased in serum and ovarian
tissues of ovarian cancer patients. ApoA1 and ApoA1 mimetic peptides can sequestrate
pro-inflammatory phospholipids, some of which are known to activate a variety of
oncogenic pathways. Besides, more intrinsic anti-tumorigenic properties, independent
from interaction with lipids, have also been described for ApoA1. We aimed to disclose
the effects of ApoA1 and a mimetic peptide on the malignant phenotype of ovarian
cancer cells, particularly regarding cell viability, invasiveness and platinum sensitization.
Methods: Cells viability was assessed by MTS assay. Extracellular matrix invasion was
assessed by transwell and spheroid invasion assays. Western blotting was performed
to evaluate the effect of test compounds on intracellular pathways. Sensitization assays
were performed in vitro and in the biologically relevant in ovo chorioallantoic membrane
model.
Results: Both ApoA1 and the mimetic peptide, at a concentration of 100 µg/mL, were
able to decrease the viability of SKOV3, CAOV3, and OVCAR3 cells (p < 0.05). The
peptide at this concentration was not able to affect the viability of immortalized non-
neoplastic ovarian cells (p > 0.05). ApoA1 decreased SKOV3 cells invasiveness at
300 µg/mL after 72 and 96 h of exposure (p < 0.05), while the ApoA1 mimetic peptide
prevented cell invasion at 50 and 100 µg/mL (p < 0.01). Treatment with 100 µg/mL
of ApoA1 mimetic peptide decreased Akt phosphorylation in SKOV3 cells (p < 0.01).
Accordingly, treatment with increasing concentrations of the peptide sensitized SKOV3,
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OVCAR3 and CAOV3 cells to cisplatin. This synergistic effect was observed both in vitro
and in ovo.
Conclusions: These results support the role of ApoA1 and ApoA1 mimetics as
suppressors of ovarian tumorigenesis and as chemo-sensitising agents.
Keywords: apolipoprotein A1, ApoA1 mimetic peptides, ovarian cancer, platinum sensitization, invasiveness
INTRODUCTION
Ovarian cancer is the most deadly gynecological neoplastic
disease among women worldwide (Coburn et al., 2017). Up
to 85% of patients with epithelial ovarian cancer who achieve
full remission after 1st line platinum-based chemotherapy will
develop recurrent disease (Foley et al., 2013). The effectiveness of
currently available treatments for this malignancy remains largely
unsatisfactory and the 5-year survival rate is as low as 46% (Miller
et al., 2016). For these reasons, new therapeutic strategies for
ovarian cancer are urgently needed.
High density lipoprotein (HDL) particles are protein-
rich lipoprotein complexes characterized by heterogeneous
composition and function, with apolipoprotein A1 (ApoA1)
being the major structural and functional component of the HDL
proteome (Kontush et al., 2015). The best-known role of this
apolipoprotein is in the maintenance of cholesterol homeostasis
by promoting reverse cholesterol transport (Heinecke, 2012).
However, HDL and ApoA1 have pleiotropic effects that
substantiate the importance of these components in several other
physiological functions (Bogan and Hennebold, 2010; Sriraman
et al., 2010; Zamanian-Daryoush et al., 2013). For example,
ApoA1 exerts an essential role in ovarian physiology and ovarian
steroidogenesis (Bogan and Hennebold, 2010) and indeed the
levels of this apolipoprotein are remarkably decreased in both
serum and ovarian tissue of patients suffering from ovarian
cancer (Stavnes et al., 2014; Wegdam et al., 2014). For this
reason, ApoA1 was included in a panel of five biomarkers for
assessing the likelihood of malignancy of an ovarian mass (Nolen
and Lokshin, 2013). In this context, higher serum ApoA1 levels
are associated with better prognosis and longer overall survival
among patients suffering from ovarian cancer (Stavnes et al.,
2014). The anti-tumorigenic properties of ApoA1 have been
recently studied (Su et al., 2010; Ganapathy et al., 2012; Gao
et al., 2012; Zamanian-Daryoush et al., 2013; Gkouskou et al.,
2016) and it was found that ApoA1 and ApoA1 mimetic peptides
can bind to pro-inflammatory pro-oncogenic phospholipids,
namely to lysophosphatidic acid (LPA) (Van Lenten et al.,
2008; Su et al., 2010; Yeh et al., 2016), whose plasma levels
are increased in approximately 90% of all ovarian cancer
patients (Bast et al., 2009). Importantly, LPA can activate a
variety of cell signaling pathways with oncogenic potential,
leading to increased survival, proliferation, motility, invasion,
neoangiogenesis and chemoresistance (Li et al., 2009; Fan et al.,
2015; Riaz et al., 2016). Furthermore, ApoA1 seems to have also
other anti-tumorigenic properties, which are independent from
LPA interaction and sequestration (Zamanian-Daryoush et al.,
2013). The research work reported in the current paper was aimed
at disclosing the effects of ApoA1 and an ApoA1 mimetic peptide
(Ac-F3,1418A-NH2) on the malignant phenotype of ovarian
cancer cells, particularly focusing on cell viability, invasiveness
and the potential to synergize with platinum.
MATERIALS AND METHODS
Cell Culture
SKOV3 cells (ATCC R©HTB-77TM) were maintained in RPMI-
1640 medium (Sigma-Aldrich, MO, United States) supplemented
with 10% fetal bovine serum (FBS), 2 mM L-glutamine and
50 U/mL penicillin/streptomycin (Invitrogen, CA, United States).
OVCAR3 cells (ATCC R©HTB-161TM) were maintained in RPMI-
1640 medium supplemented with 10% FBS, 2 mM L-glutamine,
50 U/mL penicillin/streptomycin and 0.01 mg/mL bovine
insulin (Sigma-Aldrich, MO, United States). CAOV3 cells
(ATCC R©HTB-75TM) were maintained in DMEM medium
(Sigma-Aldrich, MO, United States) supplemented with 10%
FBS, 2 mM L-glutamine and 50 U/mL penicillin/streptomycin.
SKOV3, OVCAR3, and CAOV3 cells were cultured at 37◦C in a
humidified atmosphere of 5% CO2. Immortalized non-neoplastic
human ovarian surface epithelial cells (OSEC2) was kindly
provided by Dr. Richard Edmondson (Newcastle University,
United Kingdom). OSEC2 cells were kept in RPMI-1640 medium
supplemented with 10% FBS, 2 mM L-glutamine and 50 U/mL
penicillin/streptomycin, at 33◦C in a humidified atmosphere of
5% CO2, as described (McKie et al., 2012). All cell lines were
regularly tested to exclude mycoplasma contamination.
Cell Viability and Caspase-Dependent
Apoptosis Assay
SKOV3 cells were seeded in 96-well plates (5,000 cells/well) in
full medium conditions and were allowed to attach for 24 h
at 37◦C. Cell medium was then changed to serum-free RPMI-
1640. After overnight serum starvation, cells were incubated
with increasing concentrations of ApoA1 (Sigma-Aldrich, MO,
United States; 1–100 µg/mL) for 48 h. Mitochondrial viability
was measured by CellTiter96 R© AQueous One Solution Cell
Proliferation assay (Promega, WI, United States). The results of
cell viability for each condition were normalized to the control,
which consisted of untreated cells exposed to vehicle only. Two
independent experiments were performed, and each condition
was run in triplicate. For the apoptosis assay, SKOV3 cells were
seeded in 96-well white flat bottom plates (5,000 cells/well) in
full medium conditions and were allowed to attach for 24 h
at 37◦C. Cell medium was then changed to serum-free RPMI-
1640. After overnight serum starvation, cells were incubated
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with 100 µg/mL ApoA1 for 12 and 48 h. Caspase 3/7 activation
was measured using the ApoTox-GloTM triplex assay (Promega,
WI, United States). Caspase 3/7 activity was normalized to cell
viability obtained for each condition. The results of caspase 3/7
activation were compared to the untreated control cells. Two
independent experiments were performed, and each condition
was run in triplicate.
The effect of the ApoA1 mimetic peptide (4F or Ac-F3,1418A-
NH2; sequence: acetyl-DWFKAFYDKVAEKFKEAF-NH2; JPT
Peptide Technologies, Berlin, Germany) on mitochondrial
viability was investigated in SKOV3, OVCAR3, and CAOV3 cell
lines. The toxicity of this peptide for non-neoplastic OSEC2
cells was also assessed. SKOV3, OVCAR3, and CAOV3 cells
were seeded in 96-well plates (5,000 cells/well) in full medium
conditions. Cells were allowed to attach for 24 h at 37◦C. Cells
were then kept in serum-free medium and, after overnight serum
starvation, they were incubated with increasing concentrations of
ApoA1 mimetic peptide (0.5–100 µg/mL) 1 for 48 h. Similarly,
OSEC2 cells (5,000 cells/well) were seeded in 96-well plates in
full medium conditions. Cells were allowed to attach for 24 h
at 33◦C. Cell medium was changed to serum-free RPMI-1640
and after overnight serum starvation, cells were incubated with
100 µg/mL ApoA1 mimetic peptide for 48 h. The mitochondrial
viability was measured by CellTiter96 R© AQueous One Solution
Cell Proliferation assay. The results of cell viability for each
condition were normalized to the viability of untreated cells. Two
independent experiments were performed for each cell line; each
condition was run in triplicate.
3D Tumor Spheroid Invasion Assay
SKOV3 cells were cultured in ultra-low attachment round
bottom 96-well plates, at a density of 5,000 cells/well in full
1100 µg/mL of ApoA1 corresponds to approximately 3.5 µM of protein (ApoA1
molecular weight: 28300 g/mol), while 100 µg/mL of the ApoA1 mimetic peptide
corresponds to 43 µM of peptide (4F peptide molecular weight: 2310.62 g/mol).
medium conditions. Cells were kept at 37◦C. After 3 days, the
spheroids were serum-starved for 12 h. After this period of serum
starvation, the spheroids were gently embedded in a mixture with
equal volumes of serum-free RPMI-1640 and cold liquid growth
factor reduced, phenol red-free, basement membrane Matrigel R©
matrix (BD Biosciences, NJ, United States). Low concentration
serum (0.3%) was added to stimulate invasion. ApoA1 was added
to the mixture at a concentration of 300 µg/mL, while untreated
spheroids exposed to vehicle only were used as controls. The
invasion of extracellular matrix was assessed daily for 4 days,
using an inverted microscope. Quantitative image analysis was
performed with ImageJ software (National Institutes of Health,
Bethesda, MD, United States). The invasion area was normalized
to the spheroid area at time = 0. Two independent experiments
were performed, each condition was run in triplicate.
Transwell Migration Assay
SKOV3 cells were cultured in 6-well plates, at a cell density
of 500,000 cells/well in RPMI-1640 supplemented with
10% FBS (full media conditions). Cells were allowed to
attach for 24 h at 37◦C in a humidified atmosphere of
5% CO2. Cells were then pre-treated with either 50 or
100 µg/mL ApoA1 mimetic peptide in serum free conditions.
Untreated cells, exposed to vehicle only, were used as
controls. After 24 h, 50,000 pre-treated and control cells
were seeded in the top compartment of Matrigel R© coated
8 µm pores transwell culture inserts (Corning Life Sciences,
Corning, NY, United States) in the presence of either 50 or
100 µg/mL ApoA1 mimetic peptide in serum free conditions.
Control cells were again exposed to vehicle only. Complete
medium containing 10% FBS was added to the bottom
compartment of the plate as chemoattractant. The cells
were then incubated for 2 days at 37◦C in a humidified
atmosphere of 5% CO2. Cells that had not migrated were
removed from inside the transwell with a cotton swab. Cells
were then fixed in cold methanol at −20◦C for 5 min and
FIGURE 1 | ApoA1 decreases the viability of ovarian cancer cells without affecting caspase activation. (A) SKOV3 cells were incubated with human ApoA1 up to a
concentration of 100 µg/mL in serum-free conditions for 48 h. Untreated cells were exposed to vehicle only. ApoA1 treatment significantly decreased the viability of
SKOV3 cells (Kruskal–Wallis test with Dunn’s multiple comparison post-test; p < 0.05). (B) SKOV3 cells were incubated with 100 µg/mL ApoA1 for 12 h (light gray
bars) and 48 h (dark gray bars). Caspase 3/7 activation was quantified and normalized to the number of viable cells. No differences were observed in caspase
activation between untreated cells and cells exposed to ApoA1. Differences were considered significant if p < 0.05. ∗p < 0.05.
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stained with crystal violet for 10 min. The number of cells
present in the bottom compartment of each well was then
determined using an inverted microscope. Two independent
experiments were performed, each condition was run in
duplicate.
Western Blotting
For western blot analysis SKOV3 cells were seeded in 12-
well plates (60,000 cells/well) and allowed to attach during
24 h at 37◦C. Cells were serum-starved overnight and then
treated with the ApoA1 mimetic peptide at a concentration of
50 or 100 µg/mL, for 12 and 24 h in serum-free conditions,
before cell lysis for 20 min on ice. Briefly, cells were washed
with PBS prior to collection in RIPA buffer (Sigma-Aldrich,
MO, United States) supplemented with protease inhibitor
cocktail (Roche, Basel, Switzerland) and phosphatase inhibitor
cocktail II (Calbiochem, San Diego, CA, United States) at
the manufacturers’ recommended concentrations. Total protein
concentration in the whole lysate was determined using the
BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham,
MA, United States). Lysates were incubated at 100◦C for
10 min and then separated into 10% sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE). Gels were
then transferred onto polyvinylidene difluoride membranes
(Millipore, MA, United States). Membranes were blocked with
5% bovine serum albumin (BSA; Thermo Fisher Scientific,
Waltham, MA, United States) in Tris-buffered saline polysorbate-
20 (TBST) buffer. Primary antibodies were diluted in 5%
FIGURE 2 | ApoA1 decreases the ability of ovarian cancer cells to invade the extracellular matrix. The 3D tumor spheroid invasion assay was performed in SKOV3
spheroids exposed to ApoA1 at a concentration of 300 µg/mL, and in unexposed spheroids (control). Invasion of extracellular matrix was assessed for up to 96 h.
Exposure to ApoA1 significantly decreased the ability of SKOV3 cells to invade the extracellular matrix after 72 h (Two-way ANOVA; p < 0.001) and 96 h (p < 0.05).
In (A), the relative invasion normalized to the spheroid area at time = 0 is plotted for ApoA1-treated and untreated spheroids. In (B), it is shown two spheroids,
representatives of the ApoA1-treated and control conditions, at the beginning of the experiment (time = 0) and during the course of experiment (72 and 96 h).
Differences were considered significant if p < 0.05. ∗p < 0.05, ∗∗∗p < 0.001.
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BSA in TBST buffer as follows: 1:6,000 dilution for the
calnexin antibody (ENZO Life Sciences, Farmingdale, NY,
United States); 1:2,000 dilution for both phospho-p44/42 MAPK
(ERK1/2) (Thr202/Tyr204) and p44/42 MAPK (ERK1/2) rabbit
antibodies; 1:1,000 dilution for both the phospho-Akt Ser473
and the pan Akt rabbit antibodies (Cell Signaling Technology,
MA, United States). Incubation with primary antibodies was
performed at 4◦C overnight. Horseradish peroxidase (HRP)-
conjugated polyclonal goat anti-rabbit IgG (Agilent Technology,
CA, United States) was employed at a 1:5,000 dilution
in 1% BSA in TBST buffer, for incubation for 2 h at
room temperature. Proteins were detected using ImmobilonTM
Western Chemiluminescent HRP Substrate system (Millipore,
MA, United States) and developed on X-ray film using a
Kodak SRX2000 (Rochester, NY, United States) developer
machine. Quantitative densitometry was performed using
ImageJ software (National Institutes of Health, Bethesda, MD,
United States).
In vitro Cisplatin Sensitization Assay
SKOV3, OVCAR3, and CAOV3 cells were seeded in 96-well
plates (5,000 cells/well) in full medium conditions. Cells were
allowed to attach for 24 h at 37◦C. Cells were then exposed to the
ApoA1 mimetic peptide and cisplatin in full medium conditions
for 72 h. Concentrations of the ApoA1 mimetic peptide ranged
from 50 to 150 µg/mL, while cisplatin concentrations varied
according to the sensitivity of each cell line. Mitochondrial
viability was determined by the CellTiter96 R© AQueous One
Solution Cell Proliferation assay. The results for each condition
were normalized to the control, which consisted of untreated
cells. The viability of cells incubated with the peptide in
combination with cisplatin was compared to the viability of cells
FIGURE 3 | The ApoA1 mimetic peptide decreases the viability of ovarian cancer cells without affecting non-neoplastic ovarian cells. SKOV3 (A), OVCAR3 (B), and
CAOV3 (C) cells were incubated with the ApoA1 mimetic peptide 4F up to a concentration of 100 µg/mL, in serum-free conditions for 48 h. Untreated cells were
exposed to vehicle only. Exposure to the highest concentration of the peptide decreased the viability of all the three cell lines (Kruskal–Wallis test with Dunn’s multiple
comparison post-test; p < 0.001). Immortalized non-neoplastic human ovarian surface epithelia cells (OSEC2; D) were exposed to the highest concentration of
peptide (100 µg/mL) used in the viability assay for the ovarian cancer cell lines. At this concentration the peptide did not affect the viability of OSEC2 cells.
Differences were considered significant if p < 0.05. ∗p < 0.05, ∗∗∗p < 0.001.
Frontiers in Pharmacology | www.frontiersin.org 5 January 2019 | Volume 9 | Article 1524
fphar-09-01524 January 24, 2019 Time: 16:13 # 6
Marinho et al. Platinum-Sensitizing, Anti-cancer Properties of ApoA1
exposed to cisplatin only. Two independent experiments were
performed, including four replicates per condition.
The combination index (CI) was calculated for each
concentration as the ratio between the isolated effect of both
ApoA1 mimetic peptide and cisplatin and the combined effect of
these compounds:
CI =
(
100−% viable cellspeptide alone
)+ (100−% viable cellscisplatin alone)(
100−% viable cellspeptide and cisplatin
)
A value of CI < 1 indicates that the combined effect of peptide
and cisplatin is greater than the expected additive effect (synergy),
while a value of CI> 1 results from a combined effect that is lesser
than the expected additive effect (antagonism). Additionally,
isoboles were plotted for each cell line, according to the Loewe
additivity model for synergy/antagonism calculation (Foucquier
and Guedj, 2015).
In ovo Chicken Chorioallantoic
Membrane Assay
All the procedures involving chicken embryos were performed in
agreement with Community and national legislation (Directive
2010/63/EU; Animals Scientific Procedures Act 1986) and also in
agreement with the Basel Declaration. The procedure received
prior approval by the competent National Authority (project
license: PPL70/7997; personal license: I1D60DB1A) and by
Imperial College’s Animal Welfare and Ethical Review Body.
Fertilized chicken eggs (Henry Stewart & Co. Ltd., Norfolk,
United Kingdom) were incubated at 37.5◦C with 50% relative
humidity for 3 days. On embryonic day 3, under sterile
conditions, a small hole was pierced through the egg’s taglion
using a 19-gauge needle and 2–3 mL of albumen were removed
to decrease the volume inside the egg and to ensure that the
chicken chorioallantoic membrane (CAM) is not damaged when
the egg shell is opened. A 1 cm diameter window was opened on
the egg’s shell to expose the CAM. The window was covered with
sterile film and the eggs were incubated for 6 days. At embryonic
day 9, xenografts were prepared by suspending 1 × 106 green
fluorescent protein (GFP)-transduced SKOV3 cells in 100 µL
of Matrigel R©. ApoA1 mimetic peptide and cisplatin were added
to the cell suspension, at a concentration of 100 µg/mL and
15 µM, respectively. The compounds were added separately or in
combination. Additionally, untreated cells were used as control.
A medium to large blood vessel was then gently bruised using
autoclaved round-bottom glass rods and the xenografts were
FIGURE 4 | The ApoA1 mimetic peptide hampers cancer cells invasion. A transwell migration assay was performed with SKOV3 cells exposed to the ApoA1
mimetic peptide at a concentration of 50 and 100 µg/mL, and with unexposed SKOV3 cells (control). Exposure to the ApoA1 mimetic peptide at both
concentrations significantly decreased the ability of SKOV3 cells to migrate and invade, comparatively to unexposed cells (Kruskal–Wallis test with Dunn’s post-test;
control vs. 50 µg/mL ApoA1 mimetic peptide: p = 0.0020; control vs. 100 µg/mL ApoA1 mimetic peptide: p = 0.0016). In (A), the number of cells per field is plotted
for each condition. In (B), it is shown three images representatives of each experimental condition. Differences were considered significant if p < 0.05. ∗∗p < 0.001.
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topically inoculated onto this area. After inoculation, the egg
shell window was covered with sterile tape and the eggs were
placed back in the incubator for 7 days. Tumor dimensions were
quantified at embryonic day 16 using Zeiss SteREO Discovery V8
microscope and the Zen 2.0 blue edition software (Oberkochen,
Germany).
The CI was also calculated for the in ovo CAM assay, as the
ratio between the isolated effects of 100 µg/mL ApoA1 mimetic
peptide and 15 µM cisplatin, and the combined effect of these
compounds as explained above:
CI =
(
1− xenografts sizepeptide alone
)+ (1− xenografts sizecisplatin alone)(
1− xenografts sizepeptide and cisplatin
)
Statistical Analysis
Statistical analysis was performed using GraphPad R©Prism version
5.0 (GraphPad Software Inc., CA, United States). Data are
presented as a percentage or as fold change compared to
control. Data were analyzed by two-way ANOVA, Kruskal–
Wallis, Mann–Whitney or Student’s t-test, as appropriate; a
p-value < 0.05 was considered significant.
RESULTS
Apolipoprotein A1 Decreases the
Viability of Ovarian Cancer Cells
In order to investigate whether human plasmatic ApoA1 affects
ovarian cancer cells viability, we analyzed the effect of ApoA1,
added to the extracellular medium, on the viability of SKOV3
cells. These assays were performed in serum-free conditions to
isolate the effect of human ApoA1, avoiding interferences with
bovine ApoA1 and the variety of growth factors present in the
serum for cell medium supplementation. Under these conditions,
48-h treatment with 100 µg/mL ApoA1 reduced the viability of
SKOV3 cells by 28% (Figure 1A; Kruskal–Wallis with Dunn’s
post-test; p< 0.05). This effect of ApoA1 on SKOV3 cells viability
was independent of caspase 3/7 activation, as observed after
12 and 48 h of incubation with ApoA1 (Figure 1B; two-way
ANOVA; p> 0.05).
Apolipoprotein A1 Reduces the Ability of
Ovarian Cancer Cells to Invade the
Extracellular Matrix
An important feature of cancer cells is the ability to invade the
extracellular matrix in order to metastasise to different organs.
Therefore, the effect of ApoA1 exposure on the ability of SKOV3
cells to invade the extracellular matrix was investigated in a 3D
tumor spheroid invasion assay. This assay was performed in
spheroids unexposed (control) and exposed to 300µg/mL ApoA1
(Figure 2). Invasion of the extracellular matrix was assessed
daily, for 4 days (96 h), and the invasion area for each day was
normalized to the spheroid area at time = 0. As shown in Figure 2,
ApoA1 treatment significantly decreased the ability of SKOV3
cells to invade the extracellular matrix after 72 h (Two-way
ANOVA; control: 2.97 ± 0.06; ApoA1: 1.76 ± 0.09; p < 0.001)
and 96 h of treatment (control: 2.93 ± 0.28; ApoA1: 2.11 ± 0.13;
p< 0.05).
The ApoA1 Mimetic Peptide Decreases
the Viability of Ovarian Cancer Cells
Synthetic ApoA1 mimetic peptides are able to effectively replicate
several functional features of ApoA1, therefore in the current
study the 4F ApoA1 mimetic was employed as a surrogate
for ApoA1. This peptide was tested in three different ovarian
cancer cell lines, SKOV3, OVCAR3, and CAOV3 cells. The
viability of cells treated with 100 µg/mL 4F was reduced by
28, 40 and 20%, for SKOV3, OVCAR3, and CAOV3 cells,
respectively (Figures 3A–C; Kruskal–Wallis with Dunn’s post-
test; p < 0.001 for all cell lines). The peptide at a concentration
of 50 µg/mL also reduced the viability of OVCAR3 and CAOV3
cells (Figures 3B,C; p < 0.05 for both cell lines). As shown
in Figure 3, OVCAR3 cells appear to be the most sensitive to
the ApoA1 mimetic peptide. Importantly, the ApoA1 mimetic
peptide did not affect the viability of non-neoplastic ovarian
surface epithelial OSEC2 cells (Figure 3D; Mann–Whitney,
p> 0.05).
The ApoA1 Mimetic Peptide Prevents
Cancer Cell Invasion
Cancer cell migration and invasion are recognized as essential
steps in the cascade of events that culminate in the establishment
of a metastatic tumor. The effect of the ApoA1 mimetic peptide,
at a concentration of 50 and 100 µg/mL, on the transmigration
ability of SKOV3 cells was assessed in a transwell migration
assay, employing Matrigel R© coated 8 µm pore transwells and FBS
as chemoattractant. As shown in Figures 4A,B, the treatment
with 50 or 100 µg/mL of ApoA1 mimetic peptide was able
to prevent ovarian cancer cell invasion, as the number of cells
that invaded the Matrigel and reached the bottom compartment
of the plate was significantly lower comparatively to untreated
cells (Kruskal–Wallis with Dunn’s post-test; control: 105.5
[93.8–119.8]; 50 µg/mL treatment: 29 [12–60.2]; control vs.
50 µg/mL treatment: p = 0.0020; 100 µg/mL treatment: 30
[13–61]; control vs. 100 µg/mL treatment: p = 0.0016).
The ApoA1 Mimetic Peptide Strongly
Affects Akt Phosphorylation
To better understand the mechanism behind the observed
reduction in viability, we investigated whether the incubation
with the ApoA1 mimetic peptide would affect pro-survival
pathways such as the Akt and ERK1/2 signaling cascades in
SKOV3 cells. As demonstrated in Figure 5, SKOV3 cells treated
with 100 µg/mL ApoA1 mimetic peptide showed a decrease of
approximately 50% in Akt Ser473 phosphorylation after 12 h
(Figures 5A,B; two-way ANOVA; 0.52 ± 0.08; p < 0.01) or
24 h (0.48 ± 0.10; p < 0.01) of exposure. Despite not reaching
statistical significance, a trend for increased phosphorylation of
ERK1/2 at Thr202/Tyr204 upon treatment with the peptide was
also observed. Nevertheless, this effect on ERK phosphorylation
was more pronounced after 12 h of exposure, being reduced
after 24 h of treatment (Figures 5A,C). No significant changes
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FIGURE 5 | The ApoA1 mimetic peptide strongly suppresses Akt signaling in ovarian cancer cells. After overnight serum starvation, SKOV3 cells were treated with
the ApoA1 mimetic peptide (50 or 100 µg/mL). Untreated SKOV3 cells were used as control. Cell lysates were collected 12 or 24 h after treatment and subjected to
western blot analysis. Calnexin was the loading control for these experiments. (A) Western blot for phospho Akt (Ser473) and phospho ERK1/2 (Thr202/Tyr204); (B)
densitometry for Akt Ser473 phosphorylation; (C) densitometry for ERK1/2 Thr202/Tyr204 phosphorylation. The ApoA1 mimetic peptide strongly decreased
phosphorylation of Akt at Ser473 after 12 h (two-way ANOVA; p < 0.01) and 24 h (p < 0.01) of exposure with the highest concentration of peptide (100 µg/mL).
Differences were considered significant if p < 0.05. ∗∗p < 0.001.
were observed regarding total Akt and total ERK1/2 levels
(Supplementary Figure S1). These results support the hypothesis
that the ApoA1 mimetic peptide could reduce cancer cell survival
by preferentially affecting Akt signaling. Since the activation of
the Akt pathway is key for the development of resistance to
cisplatin in ovarian cancer patients (24), these results prompted
us to evaluate the effect of this peptide on the sensitization of
ovarian cancer cells to cisplatin.
The ApoA1 Mimetic Peptide Sensitizes
Ovarian Cancer Cells to Cisplatin
To investigate the ability of the ApoA1 mimetic peptide to
induce the sensitization of ovarian cancer cells to platinum,
we exposed SKOV3, OVCAR3, and CAOV3 cells to different
concentrations of the peptide and cisplatin, and analyzed cell
viability for each condition. The results presented in Figure 6
show that, in full medium conditions, the ApoA1 mimetic
peptide sensitizes all the three ovarian cancer cell lines tested
to cisplatin. In particular, the viability for SKOV3 cells exposed
to 15 µM cisplatin only, with no peptide, was approximately
58%; while SKOV3 cells exposed to the same concentration of
cisplatin but in combination with increasing concentrations of
the peptide – 50, 100, and 150 µg/mL – presented a cell viability
of 50% (Two-way ANOVA; p < 0.05), 33% (p < 0.001) and
16% (p < 0.001), respectively. Likewise, the viability of OVCAR3
cells was significantly reduced upon concomitant treatment with
cisplatin and the ApoA1 mimetic peptide. For this cell line,
treatment with 3 µM cisplatin resulted in approximately 90%
cell viability; however, co-incubation with 50, 100, or 150 µg/mL
of 4F peptide caused a significant decrease in cell viability,
to 75% (p < 0.05), 62% (p < 0.001), and 43% (p < 0.001),
respectively. Similarly, CAOV3 cells treated with 2.5µM cisplatin
reached a cell viability of 44%, which, in combination with 100
and 150 µg/mL of the ApoA1 mimetic peptide, significantly
decreased to 24% (p < 0.001) and 5% (p < 0.001), respectively
(Figures 6A–C).
The CI for each cell line and for each concentration of
ApoA1 mimetic peptide and cisplatin is presented in Table 1.
The isoboles for synergy/antagonism calculations are presented
in Figures 6D–F. Resorting to both models, it was possible
to identify synergistic interactions between the ApoA1 mimetic
peptide and cisplatin, at different concentrations and for all the
three cell lines tested.
Effect of the ApoA1 Mimetic Peptide on
Cisplatin Sensitization in the Chicken
Chorioallantoic Membrane Model
To investigate the effect of the ApoA1 mimetic peptide in
terms of cisplatin sensitization in a more biologically relevant
system, we used the CAM assay. This in ovo model allows
the engrafting of cancer cells on the surface of the CAM,
a well-vascularised extra-embryonic tissue located underneath
Frontiers in Pharmacology | www.frontiersin.org 8 January 2019 | Volume 9 | Article 1524
fphar-09-01524 January 24, 2019 Time: 16:13 # 9
Marinho et al. Platinum-Sensitizing, Anti-cancer Properties of ApoA1
FIGURE 6 | The ApoA1 mimetic peptide sensitizes ovarian cancer cells to cisplatin. SKOV3, OVCAR3, and CAOV3 cells were co-incubated with increasing
concentrations of ApoA1 mimetic peptide, up to 150 µg/mL, and increasing concentrations of cisplatin, according to the sensitivity of each cell line. Exposure to the
peptide and cisplatin was performed in full medium conditions. After 72 h, mitochondrial cell viability was assessed. Two-way ANOVA was performed as statistical
test (A–C). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. Isoboles for assessing synergistic interactions between the ApoA1 mimetic peptide and cisplatin were also plotted
(D–F), according to the Loewe additivity model for synergy/antagonism calculation. On the horizontal axis of the isoboles, the different concentrations of ApoA1
mimetic peptide employed in the in vitro sensitization assay are represented, while in the vertical axis it is represented the concentrations of cisplatin. The
intersections represent the combined effect between the peptide and cisplatin. The color gradient ranges from dark blue (strong synergistic effect) to dark red (strong
antagonistic effect). From the isoboles analysis, it is possible to identify synergies for different concentrations of ApoA1 mimetic peptide and cisplatin.
the eggshell, in embryonated eggs. We inoculated onto the
chicken CAM GFP-transduced SKOV3 cell xenografts, exposed
in ovo to cisplatin and ApoA1 mimetic peptide, separately or in
combination.
While cisplatin alone had a modest effect on the tumor size,
we did not observe any effect of the peptide alone on the
growth of the xenografts (Figure 7). However, the combination
of the peptide and cisplatin had a more dramatic effect on
tumor growth and the size of these xenografts was significantly
smaller than those exposed to the peptide alone (Student’s t;
peptide: 1.0 ± 0.12; combination: 0.45 ± 0.06; p = 0.007) or to
cisplatin alone (cisplatin: 0.70 ± 0.11; combination: 0.45 ± 0.06;
p = 0.05) (Figure 7). Besides, the CI for the in ovo CAM
assay was 0.52 (Table 1), indicating that the combination of
peptide and cisplatin is synergistic in this biologically relevant
model. Therefore, the in ovo findings substantiate the in vitro
results demonstrating the ability of the ApoA1 mimetic to induce
cisplatin sensitization in ovarian cancer cells.
DISCUSSION
In the current study, we demonstrated the effect of ApoA1 and
the ApoA1 mimetic peptide 4F as possible suppressors of ovarian
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FIGURE 7 | The ApoA1 mimetic peptide sensitizes ovarian cancer cells to cisplatin in the biologically relevant in ovo CAM model. SKOV3 xenografts were topically
inoculated on the CAM, left untreated (control) or treated with the ApoA1 mimetic peptide (100 µg/mL), cisplatin (15 µM) or with the combination of both
(100 µg/mL peptide plus 15 µM cisplatin). Xenograft size was calculated as the area of the fluorescent tumor relative to background. Student’s t-test was performed
after testing the data normality by the Shapiro–Wilk normality test. Differences were considered significant if p < 0.05. ∗∗p < 0.01.
tumorigenesis. In particular, we observed that these compounds
can affect viability, inhibit invasion of the extracellular matrix and
induce chemosensitisation in a panel of ovarian cancer cell lines.
The anti-tumorigenic properties of both ApoA1 and ApoA1
mimetics have been recently explored in different types of
malignancies, including melanoma (Zamanian-Daryoush et al.,
2013), colorectal (Gkouskou et al., 2016), and ovarian cancer
(Su et al., 2010; Gao et al., 2011, 2012, Ganapathy et al.,
2012). For instance, transgenic animal models overexpressing
human ApoA1 showed decreased tumor development when
inoculated with melanoma and lung cancer cells, while ApoA1
knockout had the opposite effect (Zamanian-Daryoush et al.,
2013). Importantly, subcutaneous injection of human ApoA1
decreased tumor burden, prevented metastatic growth and
improved survival of mice previously inoculated with melanoma
cells, after the establishment of palpable tumors and metastasis
(Zamanian-Daryoush et al., 2013), arguing for the potential
therapeutic applications of ApoA1 for cancer at more advanced
stages. Moreover, ApoA1 knockout in a rodent model of colitis-
induced colorectal carcinogenesis was associated to exacerbated
pathological and inflammatory features and also to higher
proliferative index (Gkouskou et al., 2016). Relatively to ovarian
malignancies, overexpression of human ApoA1 also decreased
tumor volume, prevented metastatic growth and increased
survival in a transgenic mouse model of ovarian cancer (Su et al.,
2010). The anti-tumorigenic mechanisms attributed to ApoA1
are related to the modulation of the tumor microenvironment,
the inhibition of tumor neoangiogenesis, the regulation of
inflammatory signaling [e.g., through the signal transducer and
activator of transcription 3 (STAT3) pathway] and to decreased
levels of pro-invasion factors, such as matrix metalloproteinase-
9 (MMP-9) (Zamanian-Daryoush et al., 2013; Gkouskou et al.,
2016; Jia et al., 2017). Additionally, ApoA1 was demonstrated
to decrease the viability of gastric adenocarcinoma cells in vitro,
by abrogating the proliferation induced by LPA (Yeh et al.,
2016), a pro-inflammatory pro-carcinogenic lysophospholipid
that is crucially involved in the modulation of several intracellular
pathways also contributing to ovarian cancer progression (Fang
et al., 2002; Bast et al., 2009; Li et al., 2009; Fan et al., 2015; Riaz
et al., 2016; Ottevanger, 2017). Therefore, the inhibitory effect of
ApoA1 on these multiple factors could similarly contribute to the
anti-tumorigenic phenotypes we have demonstrated here.
Besides ApoA1, some ApoA1 mimetic peptides have also
been explored for their anti-tumorigenic properties. ApoA1
mimetics are synthetic amphipathic α-helical peptides that can
mimic the structure of an ApoA1 α-helix and replicate, at least
to some extent, several aspects of ApoA1 functionality (Datta
et al., 2001). However, there are some functional differences
between ApoA1 and its mimetic peptides. For instance, ApoA1
mimetic peptides show limited ability to activate the lecithin–
cholesterol acyltransferase (LCAT), unlike ApoA1 which can fully
activate this enzyme (Datta et al., 2001); in contrast, ApoA1
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TABLE 1 | Combination index (CI) for cisplatin and the ApoA1 mimetic peptide
in vitro and in ovo.
Cell line Cisplatin
concentration
(µM)
Peptide
concentration
(µg/mL)
CI
SKOV3 (in vitro) 10 50 0.98
100 0.65
150 0.69
15 50 0.88
100 0.68
150 0.74
20 50 0.68
100 0.64
150 0.78
OVCAR3 (in vitro) 1 50 1.20
100 0.87
150 0.45
3 50 0.41
100 0.64
150 0.52
5 50 0.72
100 0.84
150 0.87
CAOV3 (in vitro) 2.5 50 0.97
100 0.88
150 1.10
5 50 0.66
100 0.75
150 1.21
GFP-SKOV3 xenografts
(in ovo CAM assay)
15 100 0.52
The CI was calculated as the ratio between the isolated effects of ApoA1 mimetic
peptide and cisplatin and the combined effect of these compounds, for SKOV3,
OVCAR3, and CAOV3 cells exposed in vitro and also for GFP-transduced SKOV3
xenografts exposed to the ApoA1 mimetic peptide and cisplatin in the in ovo
chicken CAM assay. A CI value below 1 represents a synergistic effect.
mimetic peptides can bind to pro-inflammatory and oxidized
lipids, including LPA, more effectively than ApoA1 (Van Lenten
et al., 2008; Su et al., 2010). Regarding the effect of ApoA1
mimetics in ovarian cancer, Su et al. (2010) reported the beneficial
effect of two peptides, 4F and 5F (Ac-F11,14,1718A-NH2), in
terms of tumor development in vivo, after subcutaneous and
intraperitoneal injection of an epithelial ovarian cancer cell
line in mice. The mechanisms implicated in this effect were
related to the binding and sequestration of LPA and possibly
other inflammatory lipids, consequently leading to a reduction
in cellular oxidative stress and inhibition of pro-angiogenic
signaling [e.g., hypoxia-inducible factor (HIF)-1-dependendent
transcription of vascular endothelial growth factor (VEGF)]
(Saunders et al., 2010; Su et al., 2010; Gao et al., 2011, 2012;
Ganapathy et al., 2012). In regard to the anti-tumorigenic
effects reported in the present work, the involvement of LPA
sequestration seems plausible due to the high-affinity between
4F and LPA (Van Lenten et al., 2008; Su et al., 2010) and also
considering that all three ovarian cancer cell lines employed
here, unlike normal ovarian epithelial cells, produce LPA as
an autocrine/paracrine factor (Chou et al., 2004). Furthermore,
HIF-1-induced VEGF expression can lead to increased Akt
phosphorylation at Ser473 in ovarian granulosa cells and in
ovarian cancer cells (Trinh et al., 2009; Shiratsuki et al., 2016).
Additionally, cholesterol depletion in membrane lipid rafts,
promoted by both ApoA1 and the ApoA1 mimetic peptides, can
inhibit Akt signaling (Iqbal et al., 2016). However, further studies
need to be conducted to clarify the involvement and contribution
of LPA sequestration or signaling modulation in lipid rafts to the
effects mediated by ApoA1 or its mimetic peptides that we report
here.
Importantly, a large body of evidence demonstrates
hyperactivation of PI3K/Akt kinases in several malignancies
(Stronach et al., 2011; Cheung and Testa, 2013; Mabuchi et al.,
2015). This pathway not only contributes to ovarian cancer
development and tumorigenesis but has also been implicated
in the mechanism of chemoresistance of ovarian cancer cells
to platinum and other drugs, such as taxanes and doxorubicin
(Blagden and Gabra, 2009; Brasseur et al., 2017). Therefore,
targeting Akt signaling has become an appealing strategy for
overcoming chemoresistance in ovarian malignancies (Blagden
and Gabra, 2009; Stronach et al., 2011; Cheraghchi-Bashi et al.,
2015). Here we demonstrated that an ApoA1 mimetic peptide,
employed at higher concentrations than the ones reported in
previous studies (Su et al., 2010; Gao et al., 2011, 2012; Ganapathy
et al., 2012), can affect Akt signaling and cancer cells sensitivity
to platinum. Although more studies are needed to assess the
safety and tolerability of ApoA1 and ApoA1 mimetic peptides
at relevant doses for the anti-tumorigenic and chemosensitising
effect, the potential translational application of this therapeutic
approach is particularly promising (Foley et al., 2013; Miller
et al., 2016) and the use of ApoA1 or a mimetic peptide in
combination with conventional cytotoxic drugs might bring real
benefits to women affected by ovarian cancer.
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FIGURE S1 | The apoA1 mimetic peptide does not affect the levels of pan Akt or
total ERK1/2. SKOV3 cells were treated with the ApoA1 mimetic peptide (50 or
100 µg/mL) in serum free conditions. Unexposed SKOV3 cells were used as
control. Cell lysates were collected 12 or 24 h after treatment and subjected to
western blot analysis. Calnexin was employed as the loading control. (A)
Densitometry for Pan Akt; (B) densitometry for total ERK1/2.
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